Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060183 | 0.86 | MEN1 (0.37) | ALDH1A1HSD17B10HPGDL3MBTL1POLB | |
| SCHEMBL5053256 | 0.86 | CXCL8 (0.38) | ALDH1A1HSD17B10HPGDPOLBKDM4E | |
| SCHEMBL6037779 | 0.85 | ITGB3 (0.41) | ALDH1A1HSD17B10HPGDPOLBRAB9A | |
| SCHEMBL5051226 | 0.85 | CXCL8 (0.37) | ALDH1A1HSD17B10HPGDPOLBRAB9A | |
| SCHEMBL5512471 | 0.84 | ALDH1A1 (0.59) | ALDH1A1HSD17B10HPGDL3MBTL1POLB | |
| SCHEMBL5052977 | 0.83 | GAA (0.41) | ALDH1A1HSD17B10HPGDL3MBTL1POLB | |
| SCHEMBL5054477 | 0.82 | LMNA (0.41) | ALDH1A1HPGDPOLBKDM4EMAPT | |
| SCHEMBL7050371 | 0.82 | POLB (0.40) | ALDH1A1HPGDPOLBKMT2ARXFP1 | |
| SCHEMBL5054443 | 0.82 | ALDH1A1 (0.41) | ALDH1A1HSD17B10HPGDPOLBKMT2A | |
| SCHEMBL7055730 | 0.81 | MEN1 (0.41) | ALDH1A1HPGDL3MBTL1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066297-B1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2002-10-23 | — | — | EP | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002509934-A | — | — | 2002-04-02 | — | — | JP | claimed |
| EP-1066297-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-10 | — | — | EP | claimed |
| US-6121252-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITORS TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-09-19 | — | — | US | claimed |
| WO-1999050272-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-07 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| EP-1066297-B1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2002-10-23 | — | — | EP | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1066297-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-10 | — | — | EP | disclosed |
| US-6121252-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITORS TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-09-19 | — | — | US | disclosed |
| WO-1999050272-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | ALDH1A1 736/4885HSD17B10 993/4885HPGD 474/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | ALDH1A1 257/4885HSD17B10 2227/4885HPGD 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.